Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 165,703	$ 22,515
Investments	275,794	212,589
Prepaid clinical trial costs	18,896	6,769
Other current assets	5,266	2,698
Total current assets	465,659	244,571
Property and equipment, net	499	336
Operating lease right-of-use assets	51	216
Other non-current assets	349
Total assets	466,558	245,123
Current liabilities:
Accounts payable	6,407	9,366
Accrued clinical trial costs	16,826	16,708
Other accrued expenses	20,865	5,477
Operating lease liabilities, current	54	172
Total current liabilities	44,152	31,723
Operating lease liabilities, non-current		54
Convertible debt	195,324
Note payable, non-current	126,527	97,727
Total liabilities	366,003	129,504
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively
Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively	48	37
Additional paid-in capital	549,404	387,437
Accumulated deficit	(448,897)	(271,855)
Total stockholders’ equity	100,555	115,619
Total liabilities and stockholders’ equity	$ 466,558	$ 245,123

Accrued clinical trial costs.

No definition available.

Name:	CELC_AccruedClinicalTrialCosts
Namespace Prefix:	CELC_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).